Payerset Bets on AI Research Assistant to Make Price Transparency Data Usable

Federal price transparency rules took effect in 2022 with a simple premise: force insurers to publish negotiated hospital rates and let market forces do the rest. The execution has been messier. A single payer's pricing file can run to billions of rows, published in inconsistent formats and riddled with errors. The result is data that technically exists but functions, for most organizations, as noise rather than signal.

The numbers on actual usage are stark. A recent survey from the Healthcare Financial Management Association found that nearly 40% of provider organizations report limited or no meaningful use of Transparency in Coverage data when preparing for payer negotiations. That is a four-year-old regulatory mandate still failing to deliver on its core promise for a large share of the market it was designed to help.

Payerset, a four-year-old startup founded by former healthcare consultants Jerry DiMaso and Jacob Little, has built its business on closing that gap. The company says it collects every Transparency in Coverage and hospital price file published since 2022, strips out what DiMaso calls "ghost rates," and links the cleaned data to claims and remittance records. This week it launched an AI-powered research assistant designed to let health systems query that dataset in plain English and get data-backed answers without an analyst or data team standing between the question and the response.

Product Architecture and Positioning

The research assistant is not a standalone product so much as a new interface layered on top of Payerset's existing infrastructure. The company already sells Rate Explorer, which lets managed care and finance teams compare negotiated rates directly, and Data Lake, which provides API access to the same underlying data for health tech companies and consultants. The new tool is meant to make that intelligence conversational.

It ships in two forms. A Model Context Protocol server lets organizations plug Payerset's pricing, claims and policy data directly into enterprise AI tools they already use, including Claude and ChatGPT, without standing up a separate interface. A companion portal embeds the same intelligence in a chat experience inside Payerset's own platform, aimed at teams that want conversational access without building their own AI integration. That dual-track approach is a sensible hedge: it meets customers wherever their AI workflows already live rather than forcing a new tool into an already crowded stack.

The scale claims are substantial, if difficult to independently verify. Payerset says its platform draws on 20 trillion rate records retained since 2024, with more than 10 trillion more processed each quarter. DiMaso frames the value proposition in blunt terms: "It's like having extra researchers on your team." For a health system without a dedicated pricing analytics function, that framing matters more than the raw data volume. The pitch is not more data; it's less friction in using the data that already exists.

Customer use cases, as described by the company, fall into a few buckets. Providers are using the data primarily to benchmark their own reimbursement rates against competitors ahead of contract negotiations. Employers and benefits brokers are using it to assess whether their health plans are securing competitive rates, with some now independently repricing claims rather than relying solely on insurer reporting. DiMaso says the tool has also expanded into broader market intelligence, letting health systems investigate down-coding patterns and reimbursement disparities that were difficult to isolate before AI-assisted analysis.

A partnership with Jiro Health, a practice intelligence platform for clinicians, extends that reach down to individual physicians and small practices, a segment Jiro CEO Greg Field says has historically had even less visibility into market pricing than large health systems. Payerset also offers a free employer benchmark tool covering more than 129,000 self-funded employers, and the company says it plans a consumer-facing product that would let patients upload hospital bills to check whether they were charged correctly against negotiated or cash rates.

Commercial Traction and the Regulatory Backdrop

Payerset counts 31 unique customers, including nine hospital and health system clients such as Northwell Health, WakeMed, Prisma Health and Cone Health. That is a modest customer base for a company positioning itself as critical infrastructure for an industry-wide compliance mandate, and it is the figure investors and prospective enterprise buyers should weigh most carefully. Enterprise health IT sales cycles are long, and nine health system logos after four years in market is a reasonable, not explosive, pace of adoption.

What differentiates Payerset's financial profile from much of the AI health tech field is its funding history. DiMaso says the company bootstrapped to profitability, taking on a small amount of debt last year to hire additional staff and repaying it already. "We've been a profitable business since we started, and it's forced us to make technology decisions," he said, crediting the constraint with pushing the company toward custom-built data infrastructure rather than costly off-the-shelf big-data platforms. In a sector where many AI startups burn capital chasing scale before proving unit economics, a profitable, debt-light balance sheet is a meaningful point of differentiation, even if it limits the pace of expansion.

The regulatory tailwind is real and intensifying. The Trump administration has signaled it will step up enforcement of price transparency requirements, and media reports in June indicated more than 500 hospitals had received warnings or Corrective Action Plan requests since April, with more expected. DiMaso argues that rising compliance, paired with growing employer interest in using transparency data, is pushing the market toward "full transparency," which he frames as a path to deregulation: more visibility into pricing, in his view, ultimately reduces administrative burden and cost for carriers and providers alike. That is a notably favorable framing for a company whose entire business model depends on this data existing and remaining accessible.

The Bottom Line

Payerset's research assistant addresses a well-documented problem, nearly 40% of providers get little value from transparency data today, with a product that lowers the technical barrier to using it. The company's profitability and bootstrapped history are genuine strengths in a capital-intensive sector. But the customer count, 31 total and nine health systems, suggests the addressable market is still being proven out rather than captured. Enforcement momentum from CMS could accelerate demand, but investors and partners should watch adoption velocity, not just data volume, as the real signal of whether this tool becomes standard infrastructure or remains a niche solution for a handful of early adopters.